Myla explains private prescribing, pharmacy delivery and requests for NHS follow-on care. Each step has a different responsibility and does not identify a universal estradiol product.
Myla Health’s public records are especially useful at the point where a private menopause consultation may lead to another clinician taking over prescribing. The clinic describes a letter to the patient and GP, private prescriptions and pharmacy delivery. A reader considering estradiol needs to know which document makes a recommendation and which professional actually authorizes the medicine.
This review concerns UK care and official Myla information reviewed on September 28, 2026. It does not establish US availability or a particular estradiol catalog. We have not booked an appointment or tested a prescription transfer. The assessment follows the documents and charges that could surround a proposed medicine, without deciding what treatment an individual should receive.
Myla’s FAQ says patients must be on UK soil at the time of the appointment and need a UK address for medication delivery. The pricing page describes in-person appointments as well as secure video or telephone consultations. Remote access is therefore a consultation format within a stated geography, not a route to worldwide prescribing.
The Newson Clinic review is the relevant nearby comparison for UK appointment-based care. Its published rules should be checked separately rather than assumed to match Myla’s. Neither clinic’s listing in this publication establishes that a person currently outside the UK can receive treatment or have medicine sent abroad.
Myla’s pricing record describes an initial forty-five-minute consultation and a letter summarizing the discussion and recommendations for the patient and GP. The FAQ clarifies that, as a private clinic, Myla issues private rather than NHS prescriptions. A letter can communicate a proposed estradiol treatment, but it does not itself make an NHS prescription exist.
The pharmacy-record guide helps distinguish these documents. Myla says NHS availability depends on local formularies and prescribing policies and that the GP is not obliged to accept its request. Until another prescriber agrees, responsibility for a private prescription should not be assumed to have transferred simply because a letter was sent.
Myla describes prescribing regulated body-identical HRT and says it does not prescribe compounded bioidentical hormones. That is a stated formulation policy. The FAQ does not provide an exhaustive estradiol list with manufacturers, routes, strengths and package sizes, so this review does not invent one. It also separately acknowledges off-label testosterone prescribing, which limits a blanket reading of its general licensed-treatment wording.
The NHS HRT overview distinguishes hormone ingredients and delivery methods. Our patch, tablet and gel guide supports questions about the specific proposal, rather than treating the clinic’s formulation policy as a personal route recommendation or assurance that all products share identical risks.
The FAQ names Pharmacierge as an online pharmacy used for private prescriptions and says it arranges home delivery. The pricing record says private prescriptions during the first three months do not attract a prescription-provision fee, while the pharmacy still charges for the actual medicine. Later private prescription administration is listed at £35 after the initial period.
This means no prescription fee is not the same as free estradiol. The selected product, its quantity and pharmacy charge remain unverified until the actual order is quoted. Our vaginal identity guide is relevant if that route is proposed, because a general HRT prescription description does not identify a specific vaginal preparation or device.
The pricing page, marked effective from April 1, 2026, lists £290 for the initial consultation and £190 for a thirty-minute follow-up. It also advertises an installment arrangement. These are care-payment records, not a price per tube, patch or treatment month. We do not combine them with an assumed pharmacy charge to create a total that the sources do not establish.
For contrast, Defy Medical describes a US service without subscriptions but does not give a complete estradiol quote on the reviewed pages. That comparison concerns how charges are documented, not an assertion of cross-border access or clinical equivalence. In either setting, medicine identity is needed before a meaningful dispensing-price comparison can be made.
Myla’s FAQ recommends a review after treatment begins and describes further assessment when needed. Its FAQ says an annual review is required if it continues prescribing, with a longer new appointment requested when more than eighteen months have elapsed. We report those as clinic access policies, not as a monitoring schedule for a reader.
The FAQ also says an interim private prescription may be considered when a review is delayed, subject to clinical appropriateness and the absence of new concerns. It is not an automatic refill entitlement. Our medication-list review helps preserve the information needed when another service changes treatment or when a pharmacy supplies a different product description.
Myla allows relevant records to be uploaded or sent before an appointment but does not guarantee advance review. Its FAQ distinguishes making a document available from accepting clinical responsibility for an investigation, and directs urgent result concerns to the professional who requested the test. That is an important boundary when a patient brings existing treatment or laboratory paperwork.
For a proposed estradiol prescription, the useful endpoint is an agreed record of the medicine, dispensing arrangements and clinician responsible for follow-up. Administrative cancellation and refund rules remain separate from that clinical handoff. This review can trace the published process, but it cannot confirm that a GP accepted a request, a pharmacy supplied a product or a clinician reviewed an uploaded result.
Follow the source
Provider pages describe services. Medical and regulatory sources supply clinical context. None of these references substitutes for a personal assessment.